Glutamate and Myo-Inositol in 22q11 Deletion Syndrome
Author Information
Author(s): da Silva Alves Fabiana, Boot Erik, Schmitz Nicole, Nederveen Aart, Vorstman Jacob, Lavini Christina, Pouwels Petra, de Haan Lieuwe, Linszen Don, van Amelsvoort Therese
Primary Institution: Academic Medical Centre Amsterdam
Hypothesis
Glutamatergic abnormalities may be present in individuals with 22q11 deletion syndrome.
Conclusion
The study suggests that altered glutamate and myo-inositol metabolism may partially explain the psychotic symptoms and cognitive impairments seen in patients with 22q11 deletion syndrome.
Supporting Evidence
- Increased concentrations of glutamate and myo-inositol were found in the hippocampus of patients with schizophrenia.
- Patients with 22q11 deletion syndrome have a higher risk of developing schizophrenia.
- Proton magnetic resonance spectroscopy is a reliable method for measuring brain metabolites.
Takeaway
This study looked at brain chemicals in people with a genetic condition that can lead to mental health issues, finding that those with psychosis had higher levels of certain brain chemicals.
Methodology
Proton magnetic resonance spectroscopy (1H-MRS) was used to measure glutamate and other neurometabolites in the brains of adults with 22q11 deletion syndrome and healthy controls.
Potential Biases
Potential confounding factors include the effect of antipsychotic medication on metabolite concentrations.
Limitations
The study had a small sample size and did not analyze plasma samples of proline and glutamine from healthy controls.
Participant Demographics
22 adults with 22q11 deletion syndrome (12 with schizophrenia, 10 without) and 23 age-matched healthy controls.
Statistical Information
P-Value
p=0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website